The Weill Cancer Hub East has been established to explore the “interplay” between nutrition and immunotherapy in cancer ...

A new cancer therapy utilising a genetically modified herpes simplex virus type 1 (HSV-1) offers hope for late-stage patients ...

DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...

The phase 2 GIANT trial will evaluate Opdivo with or without relatlimab in IDH-wildtype newly diagnosed glioblastoma.

In March 2025, Merck Sharp & Dohme LLC announced a study are to learn if people who receive V940 and pembrolizumab are alive ...

The Toronto-based company, Altis Labs, claims its AI model is similarly superior at analyzing breast cancer and colorectal ...

The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced ...

The death of former U.S. Rep. Mia Love has brought renewed attention to an aggressive form of brain cancer that killed her at ...

City of Hope, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National ...

RNA cancer vaccines are at the forefront of next-generation cancer immunotherapy, showcasing significant potential.

PRESS RELEASE Urteste plans to start clinical trials for its pancreatic cancer test in Europe in Q3 2025 Gdańsk, Poland – 27 March 2025 – Urteste S.A. (Warsaw Stock Exchange: URT), a company ...

Researchers analyzed pivotal and confirmatory trial characteristics, outcomes, and safety data for 102 cancer drug ...